Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aglatimagene besadenovec - Candel Therapeutics

Drug Profile

Aglatimagene besadenovec - Candel Therapeutics

Alternative Names: Adenovirus herpes simplex virus thymidine kinase gene therapy - Candel Therapeutics; AdV-Tk; AdV-tk therapy - Candel Therapeutics; ADV/HSV-tk; CAN-2409; CanAtak; Cancer gene therapy - Candel Therapeutics; Gene Mediated Cytotoxic Immunotherapy; GliAtak; GMCI; OncAtak; PancAtak; ProstAtak; TKR therapy - Candel Therapeutics; Virafir

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advantagene
  • Developer Baylor College of Medicine; Bristol-Myers Squibb; Candel Therapeutics; Methodist Healthcare Ministries of South Texas; National Cancer Institute (USA); NYU Langone Medical Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Thymidine kinase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Brain cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Glioma; Non-small cell lung cancer; Pancreatic cancer; Triple negative breast cancer
  • Phase I/II Glioblastoma; Malignant pleural effusion; Ovarian cancer
  • No development reported Mesothelioma; Oesophageal cancer

Most Recent Events

  • 05 Feb 2024 Candel Therapeutics plans a potentially registrational phase III trial in prostate cancer
  • 09 Jan 2024 The Methodist Hospital System and Merck complete the phase II STOMP trial in Triple-negative-breast cancer and Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (NCT03004183)
  • 12 Dec 2023 Aglatimagene besadenovec - Candel Therapeutics receives Fast Track designation for Pancreatic cancer [Intratumoural,Injection] in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top